Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marijo Bilusic

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Cancer Immunology, Immunotherapy : CII|December 12, 2013
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinomaMarijo Bilusic, Christopher R Heery, Philip M Arlen, et al.
Frontiers in Endocrinology|August 28, 2020
A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid CancerJaydira Del Rivero, Renee N Donahue, Jennifer L Marté, et al.
Journal of Oncology Practice|June 23, 2016
Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With CancerCaitlin R Meeker, Daniel M Geynisman, Brian L Egleston, et al.
Clinical Genitourinary Cancer|December 20, 2016
Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective ReviewKyungsuk Jung, Pooja Ghatalia, Samuel Litwin, et al.
The Prostate|February 23, 2026
Metabolomic Insights Into Saliva as a Non-Invasive Surrogate for Serum to Enable Community-Based Biomarker InvestigationAlireza Abdshah, Mohammad Alyamani, Robert A Burgess, et al.
Journal for Immunotherapy of Cancer|September 7, 2019
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumorsMarijo Bilusic, Christopher R Heery, Julie M Collins, et al.
Prostate Cancer and Prostatic Diseases|January 26, 2022
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)Marijo Bilusic, Nicole J Toney, Renee N Donahue, et al.
The Oncologist|February 17, 2021
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable ChordomaPeter Joseph DeMaria, Marijo Bilusic, Deric M Park, et al.
The Oncologist|May 31, 2022
A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-EnzalutamideKeith T Schmidt, Fatima Karzai, Marijo Bilusic, et al.
Journal for Immunotherapy of Cancer|March 25, 2021
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)Marijo Bilusic, Sheri McMahon, Ravi A Madan, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Cancer Immunology, Immunotherapy : CII|December 12, 2013
Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinomaMarijo Bilusic, Christopher R Heery, Philip M Arlen, et al.
Frontiers in Endocrinology|August 28, 2020
A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid CancerJaydira Del Rivero, Renee N Donahue, Jennifer L Marté, et al.
Journal of Oncology Practice|June 23, 2016
Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With CancerCaitlin R Meeker, Daniel M Geynisman, Brian L Egleston, et al.
Clinical Genitourinary Cancer|December 20, 2016
Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective ReviewKyungsuk Jung, Pooja Ghatalia, Samuel Litwin, et al.
The Prostate|February 23, 2026
Metabolomic Insights Into Saliva as a Non-Invasive Surrogate for Serum to Enable Community-Based Biomarker InvestigationAlireza Abdshah, Mohammad Alyamani, Robert A Burgess, et al.
Journal for Immunotherapy of Cancer|September 7, 2019
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumorsMarijo Bilusic, Christopher R Heery, Julie M Collins, et al.
Prostate Cancer and Prostatic Diseases|January 26, 2022
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)Marijo Bilusic, Nicole J Toney, Renee N Donahue, et al.
The Oncologist|February 17, 2021
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Yeast-Brachyury Vaccine (GI-6301) in Combination with Standard-of-Care Radiotherapy in Locally Advanced, Unresectable ChordomaPeter Joseph DeMaria, Marijo Bilusic, Deric M Park, et al.
The Oncologist|May 31, 2022
A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-EnzalutamideKeith T Schmidt, Fatima Karzai, Marijo Bilusic, et al.
Journal for Immunotherapy of Cancer|March 25, 2021
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)Marijo Bilusic, Sheri McMahon, Ravi A Madan, et al.
Pageof 8